Cargando…
SA14 Clinical Evidence on Corticosteroid Treatment Reported in the First Year of the COVID-19 Pandemic – Comparison of Clinical Trial Publications and Treatment Recommendation
Autores principales: | Wüstner, S, Hogger, S, Gartner-Freyer, D, Friederich, A, Schley, K, Leverkus, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747423/ http://dx.doi.org/10.1016/j.jval.2022.09.2408 |
Ejemplares similares
-
Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine
por: Wüstner, Stefanie, et al.
Publicado: (2022) -
Chimeric Japanese Encephalitis Virus SA14/SA14-14-2 Was Virulence Attenuated and Protected the Challenge of Wild-Type Strain SA14
por: Huang, Rong, et al.
Publicado: (2019) -
The structure differences of Japanese encephalitis virus SA14 and SA14-14-2 E proteins elucidate the virulence attenuation mechanism
por: Liu, Xinyu, et al.
Publicado: (2018) -
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
por: Russell, Clark D, et al.
Publicado: (2020) -
Chinese expert recommendation on transnasal corticosteroid nebulization for the treatment of chronic rhinosinusitis 2021
por: Wang, Chengshuo, et al.
Publicado: (2021)